139 related articles for article (PubMed ID: 34667115)
1. Targeting CD99 Compromises the Oncogenic Effects of the Chimera EWS-FLI1 by Inducing Reexpression of Zyxin and Inhibition of GLI1 Activity.
Balestra T; Manara MC; Laginestra MA; Pasello M; De Feo A; Bassi C; Guerzoni C; Landuzzi L; Lollini PL; Donati DM; Negrini M; Magnani M; Scotlandi K
Mol Cancer Ther; 2022 Jan; 21(1):58-69. PubMed ID: 34667115
[TBL] [Abstract][Full Text] [Related]
2. MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor.
Franzetti GA; Laud-Duval K; Bellanger D; Stern MH; Sastre-Garau X; Delattre O
Oncogene; 2013 Aug; 32(33):3915-21. PubMed ID: 22986530
[TBL] [Abstract][Full Text] [Related]
3. Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis.
Ma Y; Baltezor M; Rajewski L; Crow J; Samuel G; Staggs VS; Chastain KM; Toretsky JA; Weir SJ; Godwin AK
J Mol Med (Berl); 2019 Jul; 97(7):957-972. PubMed ID: 31025088
[TBL] [Abstract][Full Text] [Related]
4. GLI1 is a central mediator of EWS/FLI1 signaling in Ewing tumors.
Joo J; Christensen L; Warner K; States L; Kang HG; Vo K; Lawlor ER; May WA
PLoS One; 2009 Oct; 4(10):e7608. PubMed ID: 19859563
[TBL] [Abstract][Full Text] [Related]
5. The EWS/FLI1 oncogenic transcription factor deregulates GLI1.
Zwerner JP; Joo J; Warner KL; Christensen L; Hu-Lieskovan S; Triche TJ; May WA
Oncogene; 2008 May; 27(23):3282-91. PubMed ID: 18084326
[TBL] [Abstract][Full Text] [Related]
6. EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.
Cidre-Aranaz F; Grünewald TG; Surdez D; García-García L; Carlos Lázaro J; Kirchner T; González-González L; Sastre A; García-Miguel P; López-Pérez SE; Monzón S; Delattre O; Alonso J
Oncogene; 2017 Feb; 36(6):766-776. PubMed ID: 27375017
[TBL] [Abstract][Full Text] [Related]
7. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.
He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K
Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381
[TBL] [Abstract][Full Text] [Related]
8. EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma.
Shimizu R; Tanaka M; Tsutsumi S; Aburatani H; Yamazaki Y; Homme M; Kitagawa Y; Nakamura T
Cancer Sci; 2018 Sep; 109(9):2907-2918. PubMed ID: 29945296
[TBL] [Abstract][Full Text] [Related]
9. A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs.
McKinsey EL; Parrish JK; Irwin AE; Niemeyer BF; Kern HB; Birks DK; Jedlicka P
Oncogene; 2011 Dec; 30(49):4910-20. PubMed ID: 21643012
[TBL] [Abstract][Full Text] [Related]
10. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
[TBL] [Abstract][Full Text] [Related]
11. Ablation of EWS-FLI1 by USP9X inhibition suppresses cancer cell growth in Ewing sarcoma.
Wang S; Huo X; Yang Y; Mo Y; Kollipara RK; Kittler R
Cancer Lett; 2023 Jan; 552():215984. PubMed ID: 36330954
[TBL] [Abstract][Full Text] [Related]
12. EWS-FLI1 regulates and cooperates with core regulatory circuitry in Ewing sarcoma.
Shi X; Zheng Y; Jiang L; Zhou B; Yang W; Li L; Ding L; Huang M; Gery S; Lin DC; Koeffler HP
Nucleic Acids Res; 2020 Nov; 48(20):11434-11451. PubMed ID: 33080033
[TBL] [Abstract][Full Text] [Related]
13. FOXM1 is an oncogenic mediator in Ewing Sarcoma.
Christensen L; Joo J; Lee S; Wai D; Triche TJ; May WA
PLoS One; 2013; 8(1):e54556. PubMed ID: 23365673
[TBL] [Abstract][Full Text] [Related]
14. Mithramycin A Radiosensitizes EWS:Fli1
Lin MY; Damron TA; Oest ME; Horton JA
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1454-1471. PubMed ID: 33373655
[TBL] [Abstract][Full Text] [Related]
15. Molecular dissection of the mechanism by which EWS/FLI expression compromises actin cytoskeletal integrity and cell adhesion in Ewing sarcoma.
Chaturvedi A; Hoffman LM; Jensen CC; Lin YC; Grossmann AH; Randall RL; Lessnick SL; Welm AL; Beckerle MC
Mol Biol Cell; 2014 Sep; 25(18):2695-709. PubMed ID: 25057021
[TBL] [Abstract][Full Text] [Related]
16. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y
Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942
[TBL] [Abstract][Full Text] [Related]
17. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
18. A novel role for keratin 17 in coordinating oncogenic transformation and cellular adhesion in Ewing sarcoma.
Sankar S; Tanner JM; Bell R; Chaturvedi A; Randall RL; Beckerle MC; Lessnick SL
Mol Cell Biol; 2013 Nov; 33(22):4448-60. PubMed ID: 24043308
[TBL] [Abstract][Full Text] [Related]
19. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK
Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820
[TBL] [Abstract][Full Text] [Related]
20. The evaluation of CD99 immunoreactivity and EWS/FLI1 translocation by fluorescence in situ hybridization in central PNETs and Ewing's sarcoma family of tumors.
Vural C; Uluoğlu O; Akyürek N; Oğuz A; Karadeniz C
Pathol Oncol Res; 2011 Sep; 17(3):619-25. PubMed ID: 21267687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]